7 Results for "

motor performance

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "motor performance" in MCE Product Catalog:

59
59 Cited Publications
Cat. No.: HY-108841
CAS No.: 143090-92-0
Purity:  99.40%
Synonyms: Kineret; Anakinra
Raleukin (Kineret) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Raleukin significantly reduces neutrophil accumulation in blood vessels and brain infarct volume as well as improves motor coordination performance in ischemic stroke mice model. Anakinra can be used to study chronic inflammatory disorders like rheumatoid arthritis and cardiovascular recurrence post-myocardial infarction .
loading...
    loading...
Cat. No.: HY-W611371
CAS No.: 61694-81-3
Target:  

TRP Channel iGluR

Research Areas:  

Neurological Disease

FP802 is an orally active potent TwinF interface inhibitor that disrupts and detoxifies the NMDAR/TRPM4 death complex. FP802 exerts powerful neuroprotective effects in the 5xFAD mouse model of Alzheimer’s disease (AD) by preventing cognitive decline, preserving neuronal structural integrity, reducing amyloid-β plaque formation, and mitigating mitochondrial pathology . FP802 stops loss of motor neurons, reduces serum neurofilament light chain (NfL) levels, improves motor performance, and extends life in a mouse model of amyotrophic lateral sclerosis (ALS). FP802 can be used for AD and ALS research .
loading...
    loading...
Cat. No.: HY-125172
CAS No.: 300670-16-0
Synonyms: Polyglutamine Aggregation inhibitor III
Target:  

Huntingtin

Research Areas:  

Others

C2-8 is an inhibitor of polyglutamine (polyQ) aggregation (IC50s=25 and 0.05 μM for recombinant HDQ51 and in PC12 cells, respectively). It also inhibits polyQ aggregation in organotypic hippocampal slice cultures isolated from R6/2 transgenic mice and reduces neurodegeneration in a dose-dependent manner in a Drosophila model of Huntington's disease. C2-8 (100 and 200 mg/kg) reduces huntingtin aggregate size, reduces neuronal atrophy, and improves motor performance in a rotarod test in the R6/2 transgenic mouse model of Huntington's disease.
loading...
    loading...
Cat. No.: HY-W611371A
CAS No.: 2490401-57-3
Target:  

TRP Channel iGluR

Research Areas:  

Neurological Disease

FP802 dihydrochloride is an orally active potent TwinF interface inhibitor that disrupts and detoxifies the NMDAR/TRPM4 death complex. FP802 dihydrochloride exerts powerful neuroprotective effects in the 5xFAD mouse model of Alzheimer’s disease (AD) by preventing cognitive decline, preserving neuronal structural integrity, reducing amyloid-β plaque formation, and mitigating mitochondrial pathology . FP802 dihydrochloride stops loss of motor neurons, reduces serum neurofilament light chain (NfL) levels, improves motor performance, and extends life in a mouse model of amyotrophic lateral sclerosis (ALS) . FP802 dihydrochloride can be used for AD and ALS research .
loading...
    loading...
Cat. No.: HY-P2590
CAS No.: 113611-68-0
Target:  

Inhibitory Antibodies

Research Areas:  

Others

Tnrnflrfamide is a neuropeptide that modulates the receptor muscles of the lobster abdominal stretch receptors and their exoskeletal muscle homologues. Tnrnflrfamide enhances motor performance, including the amplitude of excitatory postsynaptic potentials and the development of nerve-evoked tension .
loading...
    loading...
Cat. No.: HY-P12386
CAS No.: 312769-66-7
Research Areas:  

Inflammation/Immunology

cyclo-pAKKR is a mimetic of the BDNF-binding region of p75 NTR and a p75 NTR agonist. cyclo-pAKKR promotes peripheral neuron survival and peripheral nerve myelination. cyclo-pAKKR, through a p75 NTR-dependent signaling pathway, alleviates demyelination and axonal pathological damage, improves motor function performance in the experimental autoimmune neuritis (EAN) model, whereas a control peptide with an altered spatial conformation of the KKR motif does not produce such biological effects. cyclo-pAKKR can be used for research related to autoimmune neuritis .
loading...
    loading...
Cat. No.: HY-187700
Research Areas:  

Neurological Disease

BRD3290 is a GluA3-preferring AMPA receptor positive allosteric modulator with brain exposure in Mus musculus (mice) following peripheral administration. BRD3290 preferentially potentiates GluA3-containing AMPA receptors over GluA1/2-containing AMPA receptors. BRD3290 increases cerebellar cGMP levels in Mus musculus (mice). BRD3290 does not induce convulsions, alter motor function, or improve novel object recognition task performance in Mus musculus (mice) at tested doses. BRD3290 can be used for the research of schizophrenia .
loading...
    loading...